Regeneron Pharmaceuticals Inc. (REGN) has sought FDA approval of Dupixent in the expanded use of treating moderate-to-severe atopic dermatitis in children aged 6 months to 5 years. The decision date is set for June 9, 2022.Dupixent is already approved for the treatment of patients aged 6 years and older with moderate-to-severe atopic dermatitis. The drug is also approved as an add-on maintenance treatment of patients aged 6 years and older with moderate-to-severe asthma and as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis. As recently as last week, the FDA approved the drug as the first treatment for adults and children aged 12 and older with eosinophilic esophagitis.In 2021, Dupixent sales totaled $6.2 billion, of which $4.71 billion were generated in the U.S.Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement.REGN closed Thursday’s (May 26, 2022) trading at $683.44.